Nipro Corporation
https://www.nipro.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Nipro Corporation
Slow Progress: A Decade Of Cell Therapy In Japan
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Progress Or Hype? Looking At A Decade Of Cell Therapy In Japan
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting reimbursement prices. How has the sector panned out over the last decade?
Progress Or Hype? A Decade Of Cell Therapy In Japan
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Japan Approves First Coronavirus Vaccine But Hurdles Ahead?
Japanese authorities have issued their first approval for a coronavirus vaccine, to Pfizer/BioNTech’s mRNA product Comirnaty, but public vaccine hesitancy and logistics challenges could be hurdles to achieving high administration rates and effective herd immunity.
Company Information
- Industry
- In Vitro Diagnostics
- Medical Devices
-
Medical Devices
- Diagnostic Equipment & Supplies
- Implantable Devices
- Infusion Therapy Equipment and Supplies
- Monitoring Equipment & Devices
- Other Names / Subsidiaries
-
- Avantec Vascular
- Goodman Company
- Infraredx
- Nipro Medical Corporation
- Nipro North America
- Nihon Glass Shoji Co. Ltd
- Nipro ES Pharma Co., Ltd.
- Tanabe Seiyaku Hanbai Co., Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice